Evidence map›Paper›PMID 26296362›Full record

ArticleJournal of the National Cancer Institute2015

Role of Tumor Pericytes in the Recruitment of Myeloid-Derived Suppressor Cells.

JongWook Hong, Nicholas P Tobin, Helene Rundqvist, Tian Li, Marion Lavergne, Yaiza García-Ibáñez, Hanyu Qin, Janna Paulsson, Manuel Zeitelhofer, Milena Z Adzemovic and 8 more

Erratum issuedOpen access · greenAbstract read
In one paragraph

Article in Journal of the National Cancer Institute, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 47 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed, 1 pooled it
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 1 synthesis or guideline pooled it, 72 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Mechanisms of Pericyte-Mediated Cancer Metastasis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Cold and hot tumors: from molecular mechanisms to targeted therapy.Signal transduction and targeted therapy · 2024
    Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors at 1 institution in 1 country.

JongWook HongDepartment of Medical Biochemistry and Biophysics, Division of Vascular Biology, Karolinska Institute, Stockholm, Sweden (JWH, TL, ML, YGI, HQ, MZ, MZA, IN, PR, GG); Department of Oncology-Pathology, Cancer Center Karolinska, Karolinska University Hospital, Solna, Sweden (NPT, JP, JH, AÖ, JB); Department of Cell and Molecular Biology, Karolinska Institute, Stockholm, Sweden (HR, RSJ); Department of Physiology, Development, and Neuroscience, University of Cambridge, Cambridge, UK (RSJ); Department of Molecular Medicine and Surgery, Urology Laboratory, Karolinska Institute, Stockholm, Sweden (MP); Department of Urology, Karolinska University Hospital, Solna, Sweden (MP).Current affiliation: Department of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland (HQ).
Nicholas P TobinDepartment of Medical Biochemistry and Biophysics, Division of Vascular Biology, Karolinska Institute, Stockholm, Sweden (JWH, TL, ML, YGI, HQ, MZ, MZA, IN, PR, GG); Department of Oncology-Pathology, Cancer Center Karolinska, Karolinska University Hospital, Solna, Sweden (NPT, JP, JH, AÖ, JB); Department of Cell and Molecular Biology, Karolinska Institute, Stockholm, Sweden (HR, RSJ); Department of Physiology, Development, and Neuroscience, University of Cambridge, Cambridge, UK (RSJ); Department of Molecular Medicine and Surgery, Urology Laboratory, Karolinska Institute, Stockholm, Sweden (MP); Department of Urology, Karolinska University Hospital, Solna, Sweden (MP).Current affiliation: Department of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland (HQ).
Helene RundqvistDepartment of Medical Biochemistry and Biophysics, Division of Vascular Biology, Karolinska Institute, Stockholm, Sweden (JWH, TL, ML, YGI, HQ, MZ, MZA, IN, PR, GG); Department of Oncology-Pathology, Cancer Center Karolinska, Karolinska University Hospital, Solna, Sweden (NPT, JP, JH, AÖ, JB); Department of Cell and Molecular Biology, Karolinska Institute, Stockholm, Sweden (HR, RSJ); Department of Physiology, Development, and Neuroscience, University of Cambridge, Cambridge, UK (RSJ); Department of Molecular Medicine and Surgery, Urology Laboratory, Karolinska Institute, Stockholm, Sweden (MP); Department of Urology, Karolinska University Hospital, Solna, Sweden (MP).Current affiliation: Department of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland (HQ).
Tian LiDepartment of Medical Biochemistry and Biophysics, Division of Vascular Biology, Karolinska Institute, Stockholm, Sweden (JWH, TL, ML, YGI, HQ, MZ, MZA, IN, PR, GG); Department of Oncology-Pathology, Cancer Center Karolinska, Karolinska University Hospital, Solna, Sweden (NPT, JP, JH, AÖ, JB); Department of Cell and Molecular Biology, Karolinska Institute, Stockholm, Sweden (HR, RSJ); Department of Physiology, Development, and Neuroscience, University of Cambridge, Cambridge, UK (RSJ); Department of Molecular Medicine and Surgery, Urology Laboratory, Karolinska Institute, Stockholm, Sweden (MP); Department of Urology, Karolinska University Hospital, Solna, Sweden (MP).Current affiliation: Department of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland (HQ).
Marion LavergneDepartment of Medical Biochemistry and Biophysics, Division of Vascular Biology, Karolinska Institute, Stockholm, Sweden (JWH, TL, ML, YGI, HQ, MZ, MZA, IN, PR, GG); Department of Oncology-Pathology, Cancer Center Karolinska, Karolinska University Hospital, Solna, Sweden (NPT, JP, JH, AÖ, JB); Department of Cell and Molecular Biology, Karolinska Institute, Stockholm, Sweden (HR, RSJ); Department of Physiology, Development, and Neuroscience, University of Cambridge, Cambridge, UK (RSJ); Department of Molecular Medicine and Surgery, Urology Laboratory, Karolinska Institute, Stockholm, Sweden (MP); Department of Urology, Karolinska University Hospital, Solna, Sweden (MP).Current affiliation: Department of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland (HQ).
Yaiza García-IbáñezDepartment of Medical Biochemistry and Biophysics, Division of Vascular Biology, Karolinska Institute, Stockholm, Sweden (JWH, TL, ML, YGI, HQ, MZ, MZA, IN, PR, GG); Department of Oncology-Pathology, Cancer Center Karolinska, Karolinska University Hospital, Solna, Sweden (NPT, JP, JH, AÖ, JB); Department of Cell and Molecular Biology, Karolinska Institute, Stockholm, Sweden (HR, RSJ); Department of Physiology, Development, and Neuroscience, University of Cambridge, Cambridge, UK (RSJ); Department of Molecular Medicine and Surgery, Urology Laboratory, Karolinska Institute, Stockholm, Sweden (MP); Department of Urology, Karolinska University Hospital, Solna, Sweden (MP).Current affiliation: Department of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland (HQ).
Hanyu QinDepartment of Medical Biochemistry and Biophysics, Division of Vascular Biology, Karolinska Institute, Stockholm, Sweden (JWH, TL, ML, YGI, HQ, MZ, MZA, IN, PR, GG); Department of Oncology-Pathology, Cancer Center Karolinska, Karolinska University Hospital, Solna, Sweden (NPT, JP, JH, AÖ, JB); Department of Cell and Molecular Biology, Karolinska Institute, Stockholm, Sweden (HR, RSJ); Department of Physiology, Development, and Neuroscience, University of Cambridge, Cambridge, UK (RSJ); Department of Molecular Medicine and Surgery, Urology Laboratory, Karolinska Institute, Stockholm, Sweden (MP); Department of Urology, Karolinska University Hospital, Solna, Sweden (MP).Current affiliation: Department of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland (HQ).
Janna PaulssonDepartment of Medical Biochemistry and Biophysics, Division of Vascular Biology, Karolinska Institute, Stockholm, Sweden (JWH, TL, ML, YGI, HQ, MZ, MZA, IN, PR, GG); Department of Oncology-Pathology, Cancer Center Karolinska, Karolinska University Hospital, Solna, Sweden (NPT, JP, JH, AÖ, JB); Department of Cell and Molecular Biology, Karolinska Institute, Stockholm, Sweden (HR, RSJ); Department of Physiology, Development, and Neuroscience, University of Cambridge, Cambridge, UK (RSJ); Department of Molecular Medicine and Surgery, Urology Laboratory, Karolinska Institute, Stockholm, Sweden (MP); Department of Urology, Karolinska University Hospital, Solna, Sweden (MP).Current affiliation: Department of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland (HQ).
Manuel ZeitelhoferDepartment of Medical Biochemistry and Biophysics, Division of Vascular Biology, Karolinska Institute, Stockholm, Sweden (JWH, TL, ML, YGI, HQ, MZ, MZA, IN, PR, GG); Department of Oncology-Pathology, Cancer Center Karolinska, Karolinska University Hospital, Solna, Sweden (NPT, JP, JH, AÖ, JB); Department of Cell and Molecular Biology, Karolinska Institute, Stockholm, Sweden (HR, RSJ); Department of Physiology, Development, and Neuroscience, University of Cambridge, Cambridge, UK (RSJ); Department of Molecular Medicine and Surgery, Urology Laboratory, Karolinska Institute, Stockholm, Sweden (MP); Department of Urology, Karolinska University Hospital, Solna, Sweden (MP).Current affiliation: Department of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland (HQ).
Milena Z AdzemovicDepartment of Medical Biochemistry and Biophysics, Division of Vascular Biology, Karolinska Institute, Stockholm, Sweden (JWH, TL, ML, YGI, HQ, MZ, MZA, IN, PR, GG); Department of Oncology-Pathology, Cancer Center Karolinska, Karolinska University Hospital, Solna, Sweden (NPT, JP, JH, AÖ, JB); Department of Cell and Molecular Biology, Karolinska Institute, Stockholm, Sweden (HR, RSJ); Department of Physiology, Development, and Neuroscience, University of Cambridge, Cambridge, UK (RSJ); Department of Molecular Medicine and Surgery, Urology Laboratory, Karolinska Institute, Stockholm, Sweden (MP); Department of Urology, Karolinska University Hospital, Solna, Sweden (MP).Current affiliation: Department of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland (HQ).
Ingrid NilssonDepartment of Medical Biochemistry and Biophysics, Division of Vascular Biology, Karolinska Institute, Stockholm, Sweden (JWH, TL, ML, YGI, HQ, MZ, MZA, IN, PR, GG); Department of Oncology-Pathology, Cancer Center Karolinska, Karolinska University Hospital, Solna, Sweden (NPT, JP, JH, AÖ, JB); Department of Cell and Molecular Biology, Karolinska Institute, Stockholm, Sweden (HR, RSJ); Department of Physiology, Development, and Neuroscience, University of Cambridge, Cambridge, UK (RSJ); Department of Molecular Medicine and Surgery, Urology Laboratory, Karolinska Institute, Stockholm, Sweden (MP); Department of Urology, Karolinska University Hospital, Solna, Sweden (MP).Current affiliation: Department of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland (HQ).
Pernilla RoswallDepartment of Medical Biochemistry and Biophysics, Division of Vascular Biology, Karolinska Institute, Stockholm, Sweden (JWH, TL, ML, YGI, HQ, MZ, MZA, IN, PR, GG); Department of Oncology-Pathology, Cancer Center Karolinska, Karolinska University Hospital, Solna, Sweden (NPT, JP, JH, AÖ, JB); Department of Cell and Molecular Biology, Karolinska Institute, Stockholm, Sweden (HR, RSJ); Department of Physiology, Development, and Neuroscience, University of Cambridge, Cambridge, UK (RSJ); Department of Molecular Medicine and Surgery, Urology Laboratory, Karolinska Institute, Stockholm, Sweden (MP); Department of Urology, Karolinska University Hospital, Solna, Sweden (MP).Current affiliation: Department of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland (HQ).
Johan HartmanDepartment of Medical Biochemistry and Biophysics, Division of Vascular Biology, Karolinska Institute, Stockholm, Sweden (JWH, TL, ML, YGI, HQ, MZ, MZA, IN, PR, GG); Department of Oncology-Pathology, Cancer Center Karolinska, Karolinska University Hospital, Solna, Sweden (NPT, JP, JH, AÖ, JB); Department of Cell and Molecular Biology, Karolinska Institute, Stockholm, Sweden (HR, RSJ); Department of Physiology, Development, and Neuroscience, University of Cambridge, Cambridge, UK (RSJ); Department of Molecular Medicine and Surgery, Urology Laboratory, Karolinska Institute, Stockholm, Sweden (MP); Department of Urology, Karolinska University Hospital, Solna, Sweden (MP).Current affiliation: Department of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland (HQ).
Randall S JohnsonDepartment of Medical Biochemistry and Biophysics, Division of Vascular Biology, Karolinska Institute, Stockholm, Sweden (JWH, TL, ML, YGI, HQ, MZ, MZA, IN, PR, GG); Department of Oncology-Pathology, Cancer Center Karolinska, Karolinska University Hospital, Solna, Sweden (NPT, JP, JH, AÖ, JB); Department of Cell and Molecular Biology, Karolinska Institute, Stockholm, Sweden (HR, RSJ); Department of Physiology, Development, and Neuroscience, University of Cambridge, Cambridge, UK (RSJ); Department of Molecular Medicine and Surgery, Urology Laboratory, Karolinska Institute, Stockholm, Sweden (MP); Department of Urology, Karolinska University Hospital, Solna, Sweden (MP).Current affiliation: Department of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland (HQ).
Arne ÖstmanDepartment of Medical Biochemistry and Biophysics, Division of Vascular Biology, Karolinska Institute, Stockholm, Sweden (JWH, TL, ML, YGI, HQ, MZ, MZA, IN, PR, GG); Department of Oncology-Pathology, Cancer Center Karolinska, Karolinska University Hospital, Solna, Sweden (NPT, JP, JH, AÖ, JB); Department of Cell and Molecular Biology, Karolinska Institute, Stockholm, Sweden (HR, RSJ); Department of Physiology, Development, and Neuroscience, University of Cambridge, Cambridge, UK (RSJ); Department of Molecular Medicine and Surgery, Urology Laboratory, Karolinska Institute, Stockholm, Sweden (MP); Department of Urology, Karolinska University Hospital, Solna, Sweden (MP).Current affiliation: Department of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland (HQ).
Jonas BerghDepartment of Medical Biochemistry and Biophysics, Division of Vascular Biology, Karolinska Institute, Stockholm, Sweden (JWH, TL, ML, YGI, HQ, MZ, MZA, IN, PR, GG); Department of Oncology-Pathology, Cancer Center Karolinska, Karolinska University Hospital, Solna, Sweden (NPT, JP, JH, AÖ, JB); Department of Cell and Molecular Biology, Karolinska Institute, Stockholm, Sweden (HR, RSJ); Department of Physiology, Development, and Neuroscience, University of Cambridge, Cambridge, UK (RSJ); Department of Molecular Medicine and Surgery, Urology Laboratory, Karolinska Institute, Stockholm, Sweden (MP); Department of Urology, Karolinska University Hospital, Solna, Sweden (MP).Current affiliation: Department of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland (HQ).
Mirjana PoljakovicDepartment of Medical Biochemistry and Biophysics, Division of Vascular Biology, Karolinska Institute, Stockholm, Sweden (JWH, TL, ML, YGI, HQ, MZ, MZA, IN, PR, GG); Department of Oncology-Pathology, Cancer Center Karolinska, Karolinska University Hospital, Solna, Sweden (NPT, JP, JH, AÖ, JB); Department of Cell and Molecular Biology, Karolinska Institute, Stockholm, Sweden (HR, RSJ); Department of Physiology, Development, and Neuroscience, University of Cambridge, Cambridge, UK (RSJ); Department of Molecular Medicine and Surgery, Urology Laboratory, Karolinska Institute, Stockholm, Sweden (MP); Department of Urology, Karolinska University Hospital, Solna, Sweden (MP).Current affiliation: Department of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland (HQ).
Guillem GenovéDepartment of Medical Biochemistry and Biophysics, Division of Vascular Biology, Karolinska Institute, Stockholm, Sweden (JWH, TL, ML, YGI, HQ, MZ, MZA, IN, PR, GG); Department of Oncology-Pathology, Cancer Center Karolinska, Karolinska University Hospital, Solna, Sweden (NPT, JP, JH, AÖ, JB); Department of Cell and Molecular Biology, Karolinska Institute, Stockholm, Sweden (HR, RSJ); Department of Physiology, Development, and Neuroscience, University of Cambridge, Cambridge, UK (RSJ); Department of Molecular Medicine and Surgery, Urology Laboratory, Karolinska Institute, Stockholm, Sweden (MP); Department of Urology, Karolinska University Hospital, Solna, Sweden (MP).Current affiliation: Department of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland (HQ). guillem.genove@ki.se.
Karolinska University Hospital · SE

Funding

Wellcome Trust 092738
6 · The paper itself

Abstract

backgroundPericytes are members of the tumor stroma; however, little is known about their origin, function, or interaction with other tumor components. Emerging evidence suggest that pericytes may regulate leukocyte transmigration. Myeloid-derived suppressor cells (MDSC) are immature myeloid cells with powerful inhibitory effects on T-cell-mediated antitumor reactivity.

methodsWe generated subcutaneous tumors in a genetic mouse model of pericyte deficiency (the pdgfb (ret/ret) mouse) and littermate control mice (n = 6-25). Gene expression profiles from 253 breast cancer patients (stage I-III) were evaluated for clinic-pathological parameters and survival using Cox proportional hazard ratios (HRs) and 95% confidence intervals (CIs) based on a two-sided Wald test.

resultsWe report that pericyte deficiency leads to increased transmigration of Gr1(+)/CD11b(+) cells in experimentally induced tumors. Pericyte deficiency produced defective tumor vasculature, resulting in a more hypoxic microenvironment promoting IL-6 upregulation in the malignant cells. Silencing IL-6 expression in tumor cells attenuated the observed differences in MDSC transmigration. Restoring the pericyte coverage in tumors abrogated the increased MDSC trafficking to pericyte-deficient tumors. MDSC accumulation in tumors led to increases in tumor growth and in circulating malignant cells. Finally, gene expression analysis from human breast cancer patients revealed increased expression of the human MDSC markers CD33 and S100A9 with concomitant decreased expression of pericyte genes and was associated with poor prognosis (HR = 1.88, 95% CI = 1.08 to 3.25, P = .03).

conclusionsOur data uncovers a novel paracrine interaction between tumor pericytes and inflammatory cells and delineates the cellular events resulting in the recruitment of MDSC to tumors. Furthermore, we propose for the first time a role for tumor pericytes in modulating the expression of immune mediators in malignant cells by promoting a hypoxic microenvironment.

Indexed as

Cell MovementMyeloid CellsPericytesAnimalsAntigens, SurfaceBreast NeoplasmsCD11b AntigenCell HypoxiaFemaleFlow CytometryGene SilencingHumansInterleukin-6MiceNeoplasms, ExperimentalReceptors, ChemokineAntigens, SurfaceCD11b AntigenGr-1 protein, mouseInterleukin-6Receptors, Chemokine

Identifiers

PMID26296362
PMCPMC6592827
OpenAlexW2114137950

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.